Lil­ly Asia Ven­tures leads As­traZeneca spin­out's $100M push in­to Chi­na's grow­ing R&D hub in Wuxi

Three years af­ter launch­ing with three pre­clin­i­cal as­sets from As­traZeneca’s R&D cen­ter in Shang­hai and $132.5 mil­lion in cash, Dizal Phar­ma has drawn mar­quee new …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.